Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877253 | 0.80 | EGFR (0.36) | PKMMEN1NPC1HTTRAB9A | |
| SCHEMBL19267552 | 0.75 | NOS1 (0.45) | NOS1NOS2PKMADORA1ADORA2A | |
| SCHEMBL7921131 | 0.74 | RAB9A (0.42) | NOS1NOS2PKMMEN1NPC1 | |
| SCHEMBL10507830 | 0.73 | KDM4E (0.49) | ADORA1ADORA2AMEN1NPC1HTT | |
| SCHEMBL26533881 | 0.72 | ADORA1 (0.44) | NOS1NOS2ADORA1ADORA2AMEN1 | |
| SCHEMBL20321522 | 0.71 | ALDH1A1 (0.37) | PKMADORA2AMEN1NPC1HTT | |
| SCHEMBL13380476 | 0.70 | NOS1 (0.41) | NOS1NOS2PKMADORA1ADORA2A | |
| SCHEMBL12914370 | 0.69 | NOS1 (0.42) | NOS1NOS2PKMADORA1ADORA2A | |
| SCHEMBL18054021 | 0.67 | CYP1A2 (0.42) | NOS1NOS2PKMMEN1NPC1 | |
| SCHEMBL22386524 | 0.66 | NPC1 (0.47) | PKMMEN1NPC1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | NOS1 3751/4885NOS2 3409/4885PKM 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.